Impact of healthcare system reforms on business performance and financial position
First written in FY2016. 8 of 22 entries say "Restated". Latest entry: FY2026.
Sysmex moved to the "Worse" side of this theme in 2023.
0 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「Although medical cost containment policies have expanded in China, healthcare demand continued to grow, driven by economic growth in emerging countries and global population aging. In the China operations, sales of hematology instruments and reagents, as well as coagulation testing reagents, declined substantially amid the challenging environment created by medical cost containment policies. As a result, sales amounted to ¥89,296 million, down 24.2% from the previous fiscal year.」
The impact of China's medical cost containment policies was reflected in full-year results as lower sales in the hematology and coagulation fields and a 24.2% year-on-year decline in sales in the China operations. - 2026-05-14MaterialisedRevision of earnings forecasts
「Although policies to restrain medical spending have expanded in China, demand for healthcare continued to grow alongside economic growth in emerging markets and the global aging of the population.」
The environment of expanding medical cost-containment policies in China, together with lower revenue and profit in the China segment, was reflected in the full-year results. - FY2026-H1MaterialisedAnnual report
「Sales of instruments and reagents in the coagulation testing field increased, but sales of instruments and reagents in the hematology field declined amid a challenging environment caused by government-led medical cost containment policies. As a result, sales amounted to ¥43,227 million, down 20.6% year on year.」
The challenging environment created by government-led medical cost containment policies in China was reflected in lower hematology instrument and reagent sales and a 20.6% year-on-year decline in sales in the China operations. - FY2025-H1Updated factors contributing to changes in the healthcare environmentAnnual report
「In healthcare, as social security spending is optimized and healthcare functions are decentralized amid global population aging, prevention and self-medication are becoming more important, while disparities in healthcare and problems with access to healthcare are expected to continue.」
Describes, in relation to the healthcare system and environment, the optimization of social security spending, decentralization of healthcare functions, the importance of prevention and self-medication, and the expected persistence of healthcare disparities and access issues. - FY2024WorsenedAnnual report
「The sale of the Group's instruments and diagnostic reagent products generally requires regulatory approval, but approval requirements are becoming more complex and demanding in each country. This trend may increase compliance costs, and delays in responding may result in lost market opportunities, including delays in launching new products. In addition, changes to reimbursement listing systems or reductions in reimbursement points and other fees for testing in individual countries may reduce sales opportunities for our products.」
For healthcare system reform risks, specifically describes the possibility of reduced sales opportunities due to increasingly complex and demanding regulatory approval requirements, changes to reimbursement listings and lower testing fees. - FY2023WorsenedAnnual report
「In some countries where moves to protect domestic industries are evident, local assembly and production and the procurement of parts and raw materials may be required. We are working to stay abreast of the latest information while continuing efforts to transfer production to local sites. In addition, most of our instruments and diagnostic reagents require regulatory approval or registration in each country, and moves to review regulations are accelerating, making the requirements for obtaining regulatory approval more complex and demanding.」
Adds to the previous healthcare system and pharmaceutical regulatory risks the possibility of local assembly and procurement requirements arising from domestic industry protection, as well as lost market opportunities and higher response costs due to delays in regulatory compliance. - FY2022Added the increasing complexity and sophistication of pharmaceutical regulationsAnnual report
「Most of our instruments and reagents require regulatory approval or registration in each country. Although moves to review regulations are accelerating and the requirements for obtaining regulatory approval are becoming more complex and demanding, there are also indications of moves toward regulatory deregulation.」
In addition to the previous healthcare system reform risks, adds the review of pharmaceutical regulations in each country and the increasing complexity and sophistication of approval requirements as risks. - FY2022-Q3Added the use of AI and big data in overseas healthcareAnnual report
「Overseas, the application of advanced technologies such as artificial intelligence (AI) and big data analytics is progressing rapidly in response to the optimization of healthcare accompanying population aging in developed countries, expanding healthcare demand in emerging countries, needs to improve healthcare quality and services, and the growing need for preventive medicine. Further growth opportunities are expected.」
Additionally describes the progress of AI and big data analytics applications overseas and the resulting growth opportunities amid changes in healthcare systems and the healthcare environment. - FY2022-Q2Updated changes in the healthcare environment, including the new normal and digitalizationAnnual report
「In healthcare, in addition to population aging and the diversification of health and medical needs, the healthcare environment itself is undergoing substantial change as a result of the COVID-19 pandemic. In Japan, expectations are rising for new healthcare services suited to the new normal, including relieving pressure on healthcare systems caused by rising infections, ensuring a stable supply of essential materials and addressing digitalization in healthcare.」
Describes, in addition to the previous medical cost optimization and pandemic-related changes, pressure on healthcare systems, stable supplies of essential materials, digitalization in healthcare and expectations for new healthcare services. - FY2022-Q1RestatedAnnual report
「In healthcare, in addition to population aging and the diversification of health and medical needs, the healthcare system and the healthcare environment themselves may undergo substantial change worldwide, driven by the COVID-19 pandemic.」
Reiterates the possibility of changes in healthcare systems and the healthcare environment driven by population aging, diversified healthcare needs and COVID-19. - FY2021RestatedAnnual report
「The Group will continue to pursue the commercialization of life sciences, including the creation of diagnostic technologies that contribute to personalized medicine, while providing total solutions combining specimen testing instruments, specimen testing reagents, IT, and services and support, so that it can respond closely to increasingly diverse needs in an environment where policies to optimize medical costs continue and hospitals are required to improve efficiency, advance healthcare and address new testing methods.」
Reiterates the possibility that medical cost optimization policies and the need to address new testing methods may affect business performance, along with the strategy of responding through personalized medicine and total solutions. - FY2021-Q2Added the possibility of changes in the healthcare environment due to a pandemicAnnual report
「However, as the number of COVID-19 cases increases worldwide, healthcare systems are being pressed to prepare for pandemics such as this one and to review public health, creating the possibility that the healthcare environment itself may undergo substantial change.」
Describes the possibility that the healthcare environment itself may undergo substantial change as a result of pandemic preparedness and reviews of public health, in addition to the previously identified potential impact of healthcare system reform. - FY2020RestatedAnnual report
「The Group will continue to pursue the commercialization of life sciences, including the creation of diagnostic technologies that contribute to personalized medicine, while providing total solutions combining specimen testing instruments, specimen testing reagents, IT, and services and support, so that it can respond closely to increasingly diverse needs in an environment where policies to optimize medical costs continue and hospitals are required to improve efficiency, advance healthcare and address new testing methods.」
Reiterates the possibility of an impact from medical cost optimization policies and indicates a strategy of responding through diagnostic technologies for personalized medicine and total solutions. - FY2019-Q2SoftenedAnnual report
「In the United States, the review of the healthcare system reform law introduced to eliminate the uninsured has been prolonged, but its impact is limited. In China, although policies to contain medical costs are being advanced, healthcare-related demand remains solid, supported by national strategies.」
States that the review of U.S. healthcare system reform has been prolonged but its impact is limited, and explains that healthcare-related demand in China remains solid despite medical cost containment policies. - FY2019-Q1WorsenedAnnual report
「Overseas, the number of uninsured people in the United States is increasing as the healthcare system reform law introduced to eliminate the uninsured is being reviewed, while efforts to contain medical costs are accelerating in China. Healthcare-related demand, however, remains fundamentally solid.」
In addition to the previous view of healthcare system reforms, states that the number of uninsured people is increasing in the United States and efforts to contain medical costs are accelerating in China. - FY2018RestatedAnnual report
「Against a backdrop of changes in the healthcare environment, including rapid population decline and aging, advances in medical technology and rising patient expectations regarding the quality of healthcare, healthcare system reforms aimed at optimizing medical costs and efficiently providing high-quality healthcare services continue to advance. The business performance and financial position of the Group may be affected by these reforms.」
Reiterates the continuation of healthcare system reforms driven by population decline and aging, advances in medical technology and patient needs, as well as the possibility of an impact on business performance. - FY2018-Q3RestatedAnnual report
「In healthcare, the medical and healthcare sectors are included in the government's growth strategy in Japan, and further revitalization of healthcare-related industries is expected. In the United States, moves are under way to review the healthcare system reform law introduced to eliminate the uninsured. In China, policies to contain medical costs are being implemented, but healthcare-related demand overseas remains fundamentally solid.」
Reiterates the previous view of the healthcare system environment, including the review of U.S. healthcare system reform, China's medical cost containment policies and the revitalization of Japan's healthcare-related industries. - FY2017RestatedAnnual report
「Advanced Western countries are working to contain medical costs and reform their healthcare systems. In the United States, moves are under way to review the healthcare system reform law introduced to eliminate the uninsured. In China, healthcare system reforms aimed at eliminating disparities in healthcare services between urban and rural areas continue, while policies to reduce medical costs are also being implemented.」
Reiterates the healthcare system environment, including the review of U.S. healthcare system reform and China's medical cost reduction policies. - FY2017-Q3Added the U.S. policy of reviewing its healthcare systemAnnual report
「Advanced Western countries are working to contain medical costs and reform their healthcare systems. In the United States, efforts to eliminate the uninsured had continued through healthcare system reform, but the new administration has announced a policy of reviewing the system. In China, healthcare system reforms, including the health insurance system, continue with the aim of eliminating disparities in healthcare services between urban and rural areas.」
In addition to the previous view on medical cost containment and healthcare system reform, describes the new U.S. administration's policy of reviewing the healthcare system. - FY2017-Q2RestatedAnnual report
「Advanced Western countries are working to contain medical costs and reform their healthcare systems, while the United States continues efforts to eliminate the uninsured. In China, healthcare system reforms, including the health insurance system, continue with the aim of eliminating disparities in healthcare services between urban and rural areas.」
Reiterates the view that medical cost containment and healthcare system reforms continue in the West and China. - FY2017-Q1RestatedAnnual report
「Advanced Western countries are working to contain medical costs and reform their healthcare systems, while the United States continues efforts to eliminate the uninsured. In China, healthcare system reforms, including the health insurance system, continue with the aim of eliminating disparities in healthcare services between urban and rural areas.」
Reiterates the view that medical cost containment and healthcare system reforms continue in the West and China. - FY2016First statedAnnual report
「Healthcare system reforms aimed at optimizing medical costs and efficiently providing high-quality healthcare services continue to advance, and the business performance and financial position of the Group may be affected by these reforms.」
Identifies the healthcare system environment, including medical cost containment, advances in healthcare and the need to address new testing methods, as a risk.